Citadel Advisors’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-56,100
| Closed | -$1.88M | – | 14753 |
|
|
2026
Q1 | $1.88M | Sell |
56,100
-49,700
| -47% | -$1.95M | ﹤0.01% | 6195 |
|
|
2025
Q4 | $4.9M | Buy |
105,800
+16,900
| +19% | +$927K | ﹤0.01% | 4319 |
|
|
2025
Q3 | $6.01M | Buy |
88,900
+69,100
| +349% | +$5.12M | ﹤0.01% | 4023 |
|
|
2025
Q2 | $1.66M | Sell |
19,800
-422,100
| -96% | -$31.6M | ﹤0.01% | 6065 |
|
|
2025
Q1 | $31.6M | Buy |
441,900
+302,300
| +217% | +$14.7M | 0.01% | 1541 |
|
|
2024
Q4 | $6.28M | Buy |
139,600
+126,700
| +982% | +$6.56M | ﹤0.01% | 3607 |
|
|
2024
Q3 | $651K | Buy |
12,900
+6,600
| +105% | +$316K | ﹤0.01% | 7702 |
|
|
2024
Q2 | $257K | Sell |
6,300
-28,100
| -82% | -$1.19M | ﹤0.01% | 9435 |
|
|
2024
Q1 | $1.47M | Buy |
34,400
+22,300
| +184% | +$1.01M | ﹤0.01% | 6128 |
|
|
2023
Q4 | $487K | Buy |
+12,100
| New | +$344K | ﹤0.01% | 8166 |
|
|
2022
Q3 | – | Sell |
-7,340
| Closed | -$20K | – | 13527 |
|
|
2022
Q2 | $20K | Sell |
7,340
-4,987
| -40% | -$13.8K | ﹤0.01% | 12409 |
|
|
2022
Q1 | $41K | Sell |
12,327
-480
| -4% | -$2.48K | ﹤0.01% | 12921 |
|
|
2021
Q4 | $79K | Buy |
12,807
+6,927
| +118% | +$72.7K | ﹤0.01% | 12955 |
|
|
2021
Q3 | $82K | Buy |
5,880
+2,607
| +80% | +$36.4K | ﹤0.01% | 13055 |
|
|
2021
Q2 | $56K | Buy |
3,273
+1,733
| +113% | +$29.3K | ﹤0.01% | 13288 |
|
|
2021
Q1 | $29K | Sell |
1,540
-1,753
| -53% | -$56.5K | ﹤0.01% | 13035 |
|
|
2020
Q4 | $95K | Buy |
3,293
+1,786
| +119% | +$51.5K | ﹤0.01% | 10251 |
|
|
2020
Q3 | $57K | Sell |
1,507
-2,073
| -58% | -$60.6K | ﹤0.01% | 9550 |
|
|
2020
Q2 | $119K | Buy |
+3,580
| New | +$155K | ﹤0.01% | 8893 |
|
Citadel Advisors's SLNO Position: Q2 2026 in Review
Citadel Advisors sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 386,545 shares — an estimated $12.9M sold.
Citadel Advisors first reported a position in SLNO in Q2 2015 and held it in 23 quarters. The position peaked at $126M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- Citadel Advisors reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- Citadel Advisors sold 386,545 Soleno Therapeutics shares in Q2 2026, an estimated $12.9M.
- Citadel Advisors first reported a position in Soleno Therapeutics in Q2 2015 and held it in 23 quarters.
- Citadel Advisors's Soleno Therapeutics position peaked at $126M in Q2 2025.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.